Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemetrexed vs Docetaxel Cost-minimization in 2nd Line NSCLC
NCT00284778Phase 3Completed
- Sponsor
- CHU de Limoges
- Start
- Feb 2006
- Primary completion
- Dec 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pemetrexed in non-small cell lung cancer (NSCLC) (2 arms), sponsored by CHU de Limoges. Primary endpoint: Direct Medical Costs. Started Feb 2006; status: completed.
02
Drugs
pemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00284778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00284778.